For research use only. Not for therapeutic Use.
Tixagevimab（Cat No.:I042122）is a monoclonal antibody designed to target the spike protein of the SARS-CoV-2 virus, providing passive immunity against COVID-19. It is part of a combination therapy with cilgavimab, both of which are engineered to prevent the virus from entering human cells. Tixagevimab is primarily used for pre-exposure prophylaxis (PrEP) in individuals at high risk of severe COVID-19 or who cannot receive a COVID-19 vaccine. It has shown efficacy in reducing the risk of symptomatic infection and is approved for emergency use in various countries.
| CAS Number | 2420564-02-7 |
| Purity | ≥95% |
